Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators

References

• Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003 May;4(5):397–407.
   PubMed Web of Science ®Google Scholar
• Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Reviews Immunol. 2011 Jun;11(6):403–415.
   PubMed Web of Science ®Google Scholar
• Chun J, Hla T, Lynch KR, et al. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2010 Dec;62(4):579–587.
   PubMed Web of Science ®Google Scholar
• Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Reviews Immunol. 2005 Jul;5(7):560–570.
   PubMed Web of Science ®Google Scholar
• Gräler MH, Bernhardt G, Lipp M. EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. Genomics. 1998 Oct 15;53(2):164–169.
   PubMed Web of Science ®Google Scholar
• Im DS, Heise CE, Ancellin N, et al. Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J Biol Chem. 2000 May 12;275(19):14281–14286.
   PubMed Web of Science ®Google Scholar
• Keul P, Sattler K, Levkau B. HDL and its sphingosine-1-phosphate content in cardioprotection. Heart Fail Rev. 2007 Dec;12(3–4):301–306.
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun;13(6):545–556.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14;277(24):21453–21457.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nature Reviews Drug Discovery. 2010;9(11):883–897.
   PubMed Web of Science ®Google Scholar
• Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci. 2013 May 15;328(1–2):9–18.
   PubMed Web of Science ®Google Scholar
• Aktas O, Küry P, Kieseier B, et al. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol. 2010 Jul;6(7):373–382.
   PubMed Web of Science ®Google Scholar
• Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Reviews Immunol. 2008 Oct;8(10):753–763.
   PubMed Web of Science ®Google Scholar
• Takuwa Y, Okamoto Y, Yoshioka K, et al. Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. Biochim Biophys Acta. 2008 Sep;1781(9):483–488.
   PubMed Web of Science ®Google Scholar
• Kataoka H, Sugahara K, Shimano K, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol. 2005 Dec;2(6):439–448.
   PubMed Web of Science ®Google Scholar
• Kataoka H, Shimano K, Maeda Y, et al. MT-1303, a novel sphingosine 1-phosphate (S1P) receptor modulator, ameliorates experimental autoimmune encephalomyelitis (EAE) in mice. ECTRIMS: Mult Scler. 2015 Oct 8;115138:Abstract EP1317.
   Google Scholar
• Japtok L, Kleuser B. The role of sphingosine-1-phosphate receptor modulators in the prevention of transplant rejection and autoimmune diseases. Curr Opin Investig Drugs. 2009 Nov;10(11):1183–1194.
   PubMedGoogle Scholar
• Salvadori M, Budde K, Charpentier B, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2006 Dec;6(12):2912–2921.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;Feb4362(5):402–415.
   PubMed Web of Science ®Google Scholar
• Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006 Sep 14;355(11):1124–1140.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):387–401.
   PubMed Web of Science ®Google Scholar
• FDA approves first oral drug to reduce MS relapses. [ cited 22 Sep 2010]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm
   Google Scholar
• Chun J, Brinkmann V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med. 2011 Sep;12(64):213–228.
   PubMed Web of Science ®Google Scholar
• Piali L, Froidevaux S, Hess P, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011 May;337(2):547–556.
   PubMed Web of Science ®Google Scholar
• Komiya T, Sato K, Shioya H, et al. Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis. Clin Exp Immunol. 2013 Jan;171(1):54–62.
   PubMed Web of Science ®Google Scholar
• Scott F, Brooks J, Clemons B, et al. Metabolites of RPC1063, a potent and selective S1P1R modulator, contribute to in vivo efficacy. Receptos, Inc 2013. http://files.shareholder.com/downloads/AMDA-1S4LZL/0x0x674893/48ECD974-C57D-4504-9260-E10C876DE945/AAN_2013_Poster_RPC1063_Metabolites.pdf
   Google Scholar
• Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167(5):1035–1047.
   PubMed Web of Science ®Google Scholar
• Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002 Apr 12;296(5566):346–349.
   PubMed Web of Science ®Google Scholar
• Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;Jan22427(6972):355–360.
   PubMed Web of Science ®Google Scholar
• Sanna MG, Liao J, Jo E, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004 Apr 2;279(14):13839–13848.
   PubMed Web of Science ®Google Scholar
• Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol. 2007 Dec;8(12):1295–1301.
   PubMed Web of Science ®Google Scholar
• Schwab SR, Pereira JP, Matloubian M, et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science. 2005 Sep 9;309(5741):1735–1739.
   PubMed Web of Science ®Google Scholar
• Chiba K, Matsuyuki H, Maeda Y, et al. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell Mol Immunol. 2006 Feb;3(1):11–19.
   PubMed Web of Science ®Google Scholar
• Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol. 2005;23:127–159.
   PubMed Web of Science ®Google Scholar
• Christoffersen C, Obinata H, Kumaraswamy SB, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9613–9618.
   PubMed Web of Science ®Google Scholar
• Murata N, Sato K, Kon J, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J. 2000 Dec 15;352(Pt 3):809–815.
   PubMed Web of Science ®Google Scholar
• Yatomi Y, Igarashi Y, Yang L, et al. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J Biochem. 1997 May;121(5):969–973.
   PubMed Web of Science ®Google Scholar
• Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007 Apr 13;316(5822):295–298.
   PubMed Web of Science ®Google Scholar
• Yatomi Y, Ozaki Y, Ohmori T, et al. Sphingosine 1-phosphate: synthesis and release. Prostaglandins Other Lipid Mediat. 2001 Apr;64(1–4):107–122.
   PubMed Web of Science ®Google Scholar
• Pham TH, Baluk P, Xu Y, et al. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med. 2010 Jan 18;207(1):17–27.
   PubMed Web of Science ®Google Scholar
• Lo CG, Xu Y, Proia RL, et al. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med. 2005 Jan 17;201(2):291–301.
   PubMed Web of Science ®Google Scholar
• Liu CH, Thangada S, Lee MJ, et al. Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Mol Biol Cell. 1999 Apr;10(4):1179–1190.
   PubMed Web of Science ®Google Scholar
• Matsuyuki H, Maeda Y, Yano K, et al. Involvement of sphingosine 1-phosphate (S1P) receptor type 1 and type 4 in migratory response of mouse T cells toward S1P. Cell Mol Immunol. 2006 Dec;3(6):429–437.
   PubMed Web of Science ®Google Scholar
• Oo ML, Thangada S, Wu MT, et al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem. 2007 Mar 23;282(12):9082–9089.
   PubMed Web of Science ®Google Scholar
• Brossard P, Derendorf H, Xu J, et al. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013 Dec;76(6):888–896.
   PubMed Web of Science ®Google Scholar
• Brossard P, Scherz M, Halabi A, et al. Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: Favorable impact of dose up-titration. J Clin Pharmacol. 2014 Jan 9;54(2):179–188.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Schmouder R, Barilla D, et al. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol. 2004 May;44(5):532–537.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Schmouder R, Barilla D, et al. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol. 2004 May;57(5):586–591.
   PubMed Web of Science ®Google Scholar
• Olsson T, Boster A, Fernandez O, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014 Apr 8;85(11):1198–1208.
   PubMed Web of Science ®Google Scholar
• Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013 Aug;12(8):756–767.
   PubMed Web of Science ®Google Scholar
• Vaclavkova A, Chimenti S, Arenberger P, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014 Aug 8;384(9959):2036–2045.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Feagan B, Wolf D, et al. A randomized, double-blind, placebo-controlled induction trial of an oral S1P receptor modulator (RPC1063) in moderate to severe ulcerative colitis: results of the TOUCHSTONE study. Congess of European Crohn’s and Colitis Organisation; 2015 Feb 18; Barcelona.
   Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb 14;358(7):676–688.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio D, Steinmann J, Brossard P, et al. Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations. Immunopharmacol Immunotoxicol. 2015 Feb;37(1):103–109.
   PubMed Web of Science ®Google Scholar
• Krösser S, Wolna P, Fischer TZ, et al. Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm. J Clin Pharmacol. 2015 Apr 8;55(9):1051–1060.
   PubMed Web of Science ®Google Scholar
• Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008 Oct 14;71(16):1261–1267.
   PubMed Web of Science ®Google Scholar
• Mehling M, Johnson TA, Antel J, et al. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology. 2011 Feb 22;76(8 Suppl 3):S20–7.
   PubMed Web of Science ®Google Scholar
• Rudnicka J, Czerwiec M, Grywalska E, et al. Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients - preliminary study. Central-European Journal of Immunology /Polish Society for Immunology and Eleven Other Central-European Immunological Societies. 2015;40(3):354–359.
   Google Scholar
• Song ZY, Yamasaki R, Kawano Y, et al. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod. Plos One. 2014;10(4):e0124923.
   PubMed Web of Science ®Google Scholar
• Vaessen LM, van Besouw NM, Mol WM, et al. FTY720 treatment of kidney transplant patients: a differential effect on B cells, naive T cells, memory T cells and NK cells. Transpl Immunol. 2006 Apr;15(4):281–288.
   PubMed Web of Science ®Google Scholar
• Jaigirdar SA, MacLeod MK. Development and function of protective and pathologic memory CD4 T cells. Front Immunol. 2015;6:456.
   PubMed Web of Science ®Google Scholar
• Kamanaka M, Huber S, Zenewicz LA, et al. Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med. 2011 May 9;208(5):1027–1040.
   PubMed Web of Science ®Google Scholar
• Brooks J, Peach R, Boehm M, et al. RPC1063, a potent, selective S1P1 receptor modulator, is active in a therapeutic EAE model and exhibits favourable PK/PD properties in healthy volunteers. ECTRIMS: Mult Scler. 2012;18:415. 33855.
   Google Scholar
• Vogel DY, Vereyken EJ, Glim JE, et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation. 2013;10:35.
   PubMed Web of Science ®Google Scholar
• Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2007 Jan 30;115(4):501–508.
   PubMed Web of Science ®Google Scholar
• Kahan BD, Karlix JL, Ferguson RM, et al. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplant. 2003 Oct 15;76(7):1079–1084.
   PubMed Web of Science ®Google Scholar
• Center, for, Drug, Evaluation, and, Research, et al. Application number: 22–527. Clinical pharmacology and biopharmaceutics review(s) [ online] http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022527Orig1s000clinpharmr.pdf.
   Google Scholar
• David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet. 2012 Jan 1;51(1):15–28.
   PubMed Web of Science ®Google Scholar
• Zollinger M, Gschwind H-P, Jin Y, et al. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways. Drug Metab Dispos. 2011 Feb;39(2):199–207.
   PubMed Web of Science ®Google Scholar
• Novartis. Gilenya Prescribing Information. Aug 2015.
   Google Scholar
• Kovarik JM, Slade A, Voss B, et al. Ethnic sensitivity study of fingolimod in white and Asian subjects. Int J Clin Pharmacol Ther. 2007 Feb;45(2):98–109.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Lu M, Riviere G-J, et al. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. Eur J Clin Pharmacol. 2008 May;64(5):457–463.
   PubMed Web of Science ®Google Scholar
• Guerard N, Zwingelstein C, Hoch M, et al. The effect of hepatic or renal impairment on the pharmacokinetics, safety and tolerability of ponesimod, a Selective S1P receptor modulator. Basic Clin Pharmacol Toxicol. 2015 Nov 3. Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Juif P-E, Hoch M, D’Ambrosio D, et al. Biocomparison of three formulations of the S1P1 receptor modulator ponesimod in healthy subjects. Drugs R D. 2015 Jun;15(2):203–210.
   PubMedGoogle Scholar
• Hoch M, D’Ambrosio D, Wilbraham D, et al. Clinical pharmacology of ponesimod, a selective S1P1 receptor modulator, after uptitration to supratherapeutic doses in healthy subjects. Eur J Pharm Sci. 2014 Jul 19;63:147–153.
   PubMed Web of Science ®Google Scholar
• Scherz MW, Brossard P, D’Ambrosio D, et al. Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjects. J Clin Pharmacol. 2015 Jun;55(6):688–697.
   PubMed Web of Science ®Google Scholar
• Reyes M, Hoch M, Brossard P, et al. Mass balance, pharmacokinetics and metabolism of the selective S1P receptor modulator ponesimod in humans. Xenobiotica. 2014 Sep;4:1–11.
   Google Scholar
• Boehler M, Juif PE, Hoch M, et al. Absolute bioavailability of ponesimod, a selective S1P1 receptor modulator, in healthy male subjects. Eur J Drug Metab Pharmacokinet. In press.
   PubMedGoogle Scholar
• Reyes M, Hoch M, Brossard P, et al. Effects of ethnicity and sex on the pharmacokinetics and pharmacodynamics of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod: a clinical study in Japanese and Caucasian subjects. Pharmacology. 2014;94(5–6):223–229.
   PubMed Web of Science ®Google Scholar
• Timony G, Brooks J, Hartung J, et al. Pharmacokinetics and pharmacodynamics of RPC1063 and its metabolites in healthy adult volunteers (P1. 211). Neurology. 2014;82(10Supplement):P1.211–P1. 11.
   Google Scholar
• Shakeri-Nejad K, Aslanis V, Veldandi UK, et al. Pharmacokinetics, safety and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment compared to demographically matched healthy subjects (P1. 135). Neurology. 2015;84(14Supplement):P1.135.
   Google Scholar
• Xu J, Gray F, Henderson A, et al. Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine‐1‐phosphate receptor modulator, in healthy volunteers. Clin Pharmacol Drug Dev. 2014;3(3):170–178.
   PubMed Web of Science ®Google Scholar
• Krause A, Brossard P, D’Ambrosio D, et al. Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator. J Pharmacokinet Pharmacodyn. 2014 Jun;41(3):261–278.
   PubMed Web of Science ®Google Scholar
• Sarr C, Savelieva M, Ette G, et al. Modeling dose-PK-lymphocytes relationship under siponimod (BAF312) treatment to infer time to immune reconstitution. Mult Scler J. 2014;2014:89.
   Google Scholar
• Francis G, Kappos L, O’Connor P, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Sclerosis. 2014 Apr;20(4):471–480.
   PubMed Web of Science ®Google Scholar
• Hartung H, Pigeolet E, Li D, et al. The selective sphingosine 1-phosphate receptor modulator siponimod (BAF312): magnetic resonance imaging lesion and lymphocyte relationship in a phase 2 study in relapsing remitting multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2012 Oct 10–13; Lyon, France.
   Google Scholar
• Olson A, Hartung J, Timony G, et al. Safety and tolerability of orally administered RPC1063, a novel S1P1 receptor modulator, in healthy adult volunteers, results of a phase 1 study. Neurology. 2013;80:P01.178.
   Web of Science ®Google Scholar
• FDA Drug Safety Communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs. [cited 2015 Aug 8]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm456919.htm.
   Google Scholar
• Receptos Prospectus. [cited 2013 May 8]. Available from: http://www.nasdaq.com/markets/ipos/filing.ashx?filingid=8871010.
   Google Scholar
• European Medicines Agency. Gilenya 0.5mg hard capsules - Summary of Product Characteristics. Mar 2016.
   Google Scholar
• U.S. Food and Drug Administration. GILENYA (fingolimod) capsules, for oral use HIGHLIGHTS OF PRESCRIBING INFORMATION. Feb 2016.
   Google Scholar
• Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12;387(10023):1075–1084.
   PubMed Web of Science ®Google Scholar
• Selmaj K, Arnold D, Comi G, et al. Safety and tolerability results of the phase 2 portion of the RADIANCE trial: a randomized, double-blind, placebo-controlled trial of oral RPC1063 in relapsing multiple sclerosis (P7. 199). Neurology. 2015;84(14Supplement):P7.199.
   Google Scholar
• Liu J, Zhang C, Tao W, et al. Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke. Int J Neurosci. 2013 Mar;123(3):163–169.
   PubMed Web of Science ®Google Scholar
• Hasegawa Y, Suzuki H, Sozen T, et al. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke. 2010 Feb;41(2):368–374.
   PubMed Web of Science ®Google Scholar
• Kraft P, Gob E, Schuhmann MK, et al. FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke. 2013 Nov;44(11):3202–3210.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Fu Y, Tian D, et al. Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. Circulation. 2015 Sep 22;132(12):1104–1112.
   PubMed Web of Science ®Google Scholar
• Karliner JS. Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim Biophys Acta. 2013 Jan;1831(1):203–212.
   PubMed Web of Science ®Google Scholar
• Keul P, Tolle M, Lucke S, von Wnuck Lipinski K, Heusch G, Schuchardt M, et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):607–613.
   PubMed Web of Science ®Google Scholar
• Wang G, Kim RY, Imhof I, et al. The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction. J Cardiovasc Pharmacol. 2014 Feb;63(2):132–143.
   PubMed Web of Science ®Google Scholar
• Sattler K, Graler M, Keul P, et al. Defects of high-density lipoproteins in coronary artery disease caused by low sphingosine-1-phosphate content: correction by sphingosine-1-phosphate-loading. J Am Coll Cardiol. 2015 Sep 29;66(13):1470–1485.
   PubMed Web of Science ®Google Scholar
• You S, Piali L, Kuhn C, et al. Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes. Plos One. 2013;8(10):e77296.
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Ayash L, Lazarus HM, et al. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant. 2001 Jul;28(2):121–129.
   PubMed Web of Science ®Google Scholar
• Koyrakh L, Roman MI, Brinkmann V, et al. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2005 Mar;5(3):529–536.
   PubMed Web of Science ®Google Scholar
• Sanna MG, Vincent KP, Repetto E, et al. Bitopic sphingosine 1-phosphate receptor 3 (S1P3) antagonist rescue from complete heart block: pharmacological and genetic evidence for direct S1P3 regulation of mouse cardiac conduction. Mol Pharmacol. 2016 Jan;89(1):176–186.
   PubMed Web of Science ®Google Scholar
• Schmouder R, Hariry S, David OJ. Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol. 2012 Apr;68(4):355–362.
   PubMed Web of Science ®Google Scholar
• Legangneux E, Gardin A, Johns D. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br J Clin Pharmacol. 2013 Mar;75(3):831–841.
   PubMed Web of Science ®Google Scholar
• Forrest M, Sun SY, Hajdu R, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004 May;309(2):758–768.
   PubMed Web of Science ®Google Scholar
• DiMarco J, O’Connor P, Cohen J, et al. First-dose effect of fingolimod: pooled safety data from two phase 3 studies (TRANSFORMS and FREEDOMS)(P830). Mult Sclerosis. 2010;16(Suppl 10):S290.
   Google Scholar
• Hoch M, Vaclavkova A, Krause A, et al. A novel gradual up-titration regimen mitigates the first-dose effects of ponesimod, a selective S1P1 receptor modulator. Clin Ther. 2015;37(8):e36–e37.
   Google Scholar
• Biswal S, Polus F, Pal P, et al. Pharmacokinetic and pharmacodynamic interaction of siponimod (BAF312) and propranolol in healthy subjects. Int J Clin Pharmacol Ther. 2015 Oct;53(10):855–865.
   PubMed Web of Science ®Google Scholar
• Schmouder R, Serra D, Wang Y, et al. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol. 2006 Aug;46(8):895–904.
   PubMed Web of Science ®Google Scholar
• Hoch M, Darpo B, Brossard P, et al. Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals. Basic Clin Pharmacol Toxicol. 2015 May;116(5):429–437.
   PubMed Web of Science ®Google Scholar
• Shakeri-Nejad K, Aslanis V, Veldandi UK, et al. Effects of therapeutic and supratherapeutic doses of siponimod (BAF312) on cardiac repolarization in healthy subjects. Clin Ther. 2015 Nov 1;37(11):2489–505e2.
   PubMed Web of Science ®Google Scholar
• Simula S, Laitinen T, Laitinen TM, et al. Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis. Mult scler 2015 Sep 11 Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Racca V, Di Rienzo M, Cavarretta R, et al. Fingolimod effects on left ventricular function in multiple sclerosis. Mult Sclerosis. 2016 Feb;22(2):201–211.
   PubMed Web of Science ®Google Scholar
• New recommendations to minimise risks of the rare brain infection PML and a type of skin cancer with Gilenya. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002447.jsp&mid=WC0b01ac058004d5c1: European Medicines Agency.
   Google Scholar